Clinical Assessment of Postoperative Immunochemotherapy for Non-Small Cell Lung Cancer

Abstract

A study of postoperative adjuvant chemotherapy according to cell type and curability, either combined with or without immunotherapy using OK-432 was carried out in 138 patients with lung cancer who underwent resective surgery. Administration of OK-432 was selected by randomization.
Of the total number of lung cancer cases, 123 patients were evaluable.
Five-year survival rates were 66.3% in OK-432 group (A), and 51.0% in control group (B), with no significant differences between the two groups. However, in patients who were curatively resected, the 5-year survival rate of the OK-432 group were significantly better than that of the control group (group A; 70.9%, group B; 50.8%, p<0.05), in particular in the adenocarcinoma group and Stage I group (p<0.05).
Therefore, the postoperative administration of OK-432 with chemotherapy contributed to improve the survival rate of curatively operated patients with lung cancer.